What Arinna Lifesciences does

Arinna Lifesciences Ltd. is an India-based specialty pharmaceutical company founded in 2013 and headquartered in Ahmedabad, Gujarat, that develops, markets, and distributes branded generic formulations focused on central nervous system (CNS) and neuro-psychiatric therapies. The company operates a portfolio of more than 60 brands and 140+ SKUs spanning 15 therapeutic categories — including antiepileptics, antidepressants, antipsychotics, anxiolytics, neuropathic-pain treatments, stroke and bipolar-disorder medications, anti-migraine and anti-Parkinson's drugs — marketed through two dedicated divisions, ALANZA and ALEXAA. The portfolio is contract-manufactured via five WHO-GMP-certified partner facilities, while Arinna retains full responsibility for brand development, regulatory affairs, and field commercialization.

Arinna's go-to-market is a conventional Indian branded-generics field-sales model: a medical-representative network engages more than 4,000 prescribing physicians across 23+ states, supported by 18 regional offices (CFAs), 684+ stockists/distributors, central warehouses in Ahmedabad and Meerut, and more than 5,000 retail pharmacy outlets. Revenue is generated almost entirely from domestic one-time sales of these branded formulations, with reported FY25 turnover of ₹71.5 crore (~9.8% YoY growth) and 9M-FY26 revenue of ₹56.7 crore with ₹9.5 crore EBITDA.

In April 2026, Rubicon Research acquired an 85% controlling equity stake in Arinna for approximately ₹175.92 crore (₹200 crore enterprise value on a cash-and-debt-free basis), converting Arinna into a majority-owned subsidiary and positioning its established CNS distribution platform as the launch vehicle for Rubicon's US pipeline of specialty products and drug-device combinations in the Indian market. Prior to that transaction, the company had received growth-capital backing from Motilal Oswal Private Equity across two earlier fund vintages and a ₹40 crore 2026 round.

Name

Arinna Lifesciences

Legal name

Arinna Lifesciences Ltd.

Website

https://arinnalifesciences.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

Arinna Lifesciences is an India-based specialty pharmaceutical company that markets branded generic CNS and neuro-psychiatric formulations across 15 therapy areas, distributing 60+ brands to 4,000+ prescribers and 5,000+ retail chemists through a field-sales model in India.

Ownership category

akta.pro rank

Product category

CNS and neuro-psychiatric pharmaceutical formulations

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• CNS pharmaceuticals
• Neuro-psychiatric formulations
• Antiepileptic drugs
• Antidepressant medications
• Branded generic drugs

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Arinna generates revenue through the sale of branded pharmaceutical products in the CNS and neuro-psychiatric segment. The company markets over 60 brands across chronic therapies including antiepileptics, antidepressants, antipsychotics, anxiolytics, anti-migraine, and other CNS medications. Revenue primarily comes from domestic formulations sales in India with FY25 turnover of ₹71.5 crore.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Arinna Lifesciences develops and markets branded finished-dosage pharmaceutical formulations in the central nervous system (CNS) and neuro-psychiatric therapeutic segments for the Indian market. Its portfolio includes 60+ brands and 140+ SKUs across antiepileptics, antidepressants, antipsychotics, anxiolytics, neuropathic pain, stroke, migraine, Parkinson's, bipolar disorder, and dyslipidemia therapies, sold through 684+ distributors and 5,000+ retail chemists. Manufacturing is outsourced to five WHO GMP certified contract manufacturing partners.

Product overview

Arinna Lifesciences is a specialty pharmaceutical company focused on CNS (central nervous system) and neuro-psychiatric therapies in the Indian market. The company operates a portfolio of over 60 brands across 15 therapeutic categories including antiepileptic drugs (AMVALOR, CARBESTA, FRITOLEV, ORESTA, DIRESTA, LAMRIGA, OXELTRA, TORMAP), neuropathic pain medications (ARIGABA, PYROPE), anxiolytic drugs (LONAFEST, ETIZORAM, LORANZA), schizophrenia treatments (OLIRAMP, ROSPITRIL, SULPIDON), antidepressants (TALOPREX, PATROXTA), bipolar disorder medications (QTRIPIL), stroke treatments (STROZINA), migraine medications (MIGIPLEX), Parkinson's drugs (PARKINTA), dyslipidemia treatments (ROZUPREX, ATVAROZ), and supportive therapies including vitamins and digestive medications. The company operates through two marketing divisions (ALANZA and ALEXAA) and has launched over 42 brands with more than 140 SKUs.

Differentiator

Problem solved

Functional benefit

Brands

• ALANZA: Marketing division focusing on CNS products including antiepileptics, antidepressants, anxiolytics, and neuropathic pain treatments.
• ALEXAA

Products and services

• AMVALOR (Sodium Valproate / Valproate Chrono) Sodium Valproate extended-release and syrup formulations marketed for the treatment of epilepsy. Available in multiple strengths (200 mg, 300 mg, 500 mg tablets and 200mg/5ml syrup).
• CARBESTA (Carbamazepine) Carbamazepine immediate and extended-release tablets for epilepsy, available in 200 mg, CR 200 mg, and CR 400 mg strengths.
• FRITOLEV (Levetiracetam) Levetiracetam tablets, extended-release tablets, oral solution, and injection marketed for epilepsy, available in 250 mg, 500 mg, 750 mg, 1000 mg, XR 500 mg, XR 750 mg, XR 1000 mg, 100 ml solution, and 5 ml injection.
• ORESTA (Clobazam) Clobazam tablets in 5 mg, 10 mg, and 20 mg strengths marketed for epilepsy.
• DIRESTA (Divalproex Sodium) Divalproex Sodium immediate and extended-release (OD) tablets for epilepsy, in 250 mg, 500 mg, OD 250 mg, OD 500 mg, OD 750 mg, and OD 1000 mg strengths.
• LAMRIGA (Lamotrigine) Lamotrigine dispersible tablets in 25 mg, 50 mg, and 100 mg strengths for epilepsy.
• OXELTRA (Oxcarbazepine) Oxcarbazepine tablets in 150 mg, 300 mg, 450 mg, and 600 mg strengths for epilepsy.
• TORMAP (Topiramate) Topiramate tablets in 25 mg, 50 mg, and 100 mg strengths for epilepsy.
• ARIGABA (Gabapentin) Gabapentin tablets and combination products (with Methylcobalamin and with Nortriptyline) for neuropathic pain, in 100 mg, 300 mg, 400 mg, ME 100 mg, ME 300 mg, and NT strengths.
• PYROPE (Pregabalin) Pregabalin 50 mg and 75 mg capsules, and Pregabalin 75 mg + Nortriptyline 10 mg (PYROPE NT) tablets for neuropathic pain.
• LONAFEST (Clonazepam) Clonazepam mouth-dissolving tablets in 0.25 mg, 0.5 mg, 1 mg, and 2 mg strengths for anxiety.
• ETIZORAM (Etizolam) Etizolam mouth-dissolving tablets in 0.25 mg, 0.5 mg, and 1 mg strengths for anxiety.
• LORANZA (Lorazepam) Lorazepam 1 mg and 2 mg tablets and 2 ml injection for anxiety.
• OLIRAMP (Olanzapine) Olanzapine mouth-dissolving tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg strengths for schizophrenia.
• ROSPITRIL (Risperidone) Risperidone mouth-dissolving tablets in 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg strengths, plus Risperidone + Trihexyphenidyl combination products (PLUS 2, PLUS 3, PLUS 4) for schizophrenia.
• SULPIDON (Amisulpride) Amisulpride immediate-release and controlled-release (OD) tablets in 50 mg, 100 mg, 200 mg, 300 mg, OD 100 mg, OD 200 mg, and OD 300 mg strengths for schizophrenia.
• STROZINA (Citicoline) Citicoline 500 mg and 1000 mg tablets, Citicoline 250 mg/ml injection (2 ml and 4 ml), Citicoline syrup 500 mg/5 ml, and Citicoline 500 mg + Piracetam 800 mg (STROZINA PLUS) for stroke treatment and supportive therapy.
• SAMION (Methylcobalamin / Mecobalamin) Methylcobalamin 500 mcg tablets, Mecobalamin 500 mcg/ml injection, and combination products SAMION OD and SAMION D3 with alpha lipoic acid, folic acid, pyridoxine, and vitamin D3 for vitamin supplementation.
• TALOPREX (Escitalopram) Escitalopram tablets in 5 mg, 10 mg, and 20 mg strengths, plus combination products with Clonazepam (TALOPREX LS 5, LS 10, PLUS 5, PLUS 10, PLUS 20) for depression.
• PATROXTA (Paroxetine) Paroxetine controlled-release tablets in 12.5 mg, 25 mg, and 37.5 mg strengths, plus PATROXTA PLUS 12.5 and PLUS 25 combinations with Clonazepam for depression.
• ETIZORAM PLUS (Etizolam + Escitalopram) Etizolam 0.5 mg + Escitalopram 5 mg (PLUS 5) and Etizolam 0.5 mg + Escitalopram 10 mg (PLUS 10) tablets for depression with anxiety.
• ROLMIZAC (Rabeprazole) and FRITOPAN DSR (Pantoprazole + Domperidone) Rabeprazole 20 mg tablets, Rabeprazole 20 mg + Domperidone SR 30 mg capsules (ROLMIZAC D), and Pantoprazole 40 mg + Domperidone 30 mg SR tablets (FRITOPAN DSR) for dyspepsia.
• QTRIPIL (Quetiapine) Quetiapine immediate-release tablets in 25 mg, 50 mg, and 100 mg strengths, plus sustained-release (SR) tablets in 100 mg, 200 mg, and 300 mg strengths for bipolar disorder.
• ROZUPREX (Rosuvastatin) and ATVAROZ (Atorvastatin) Rosuvastatin tablets in 5 mg, 10 mg, 20 mg, and 40 mg strengths for dyslipidemia and secondary stroke prevention, plus Atorvastatin tablets in 5 mg, 10 mg, 20 mg, and 40 mg strengths for dyslipidemia management.
• MIGIPLEX (Flunarizine + Propranolol SR) Flunarizine 5 mg or 10 mg combined with Propranolol SR 40 mg tablets for migraine prophylaxis and treatment.
• PARKINTA (Trihexyphenidyl) Trihexyphenidyl 2 mg dispersible tablets in 10, 50, and 100 tablet packs for the treatment of Parkinson's disease.
• SAMION D3 and SAMION OD (Vitamin + antioxidant combinations) Methylcobalamin/Mecobalamin + Alpha Lipoic Acid + Folic Acid + Pyridoxine + Vitamin D3 (SAMION D3) and Mecobalamin + Folic Acid + Pyridoxine + Alpha Lipoic Acid (SAMION OD) tablets marketed as vitamin and antioxidant supplements.
• VOXINIX (Fluvoxamine) Fluvoxamine 50 mg and 100 mg immediate-release tablets, plus Fluvoxamine CR 50 mg and CR 100 mg controlled-release tablets for depression and OCD.

Named customers2 records

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Rubicon ResearchcoreStrategic or Co-development Partner · 15 April 2026Rubicon Research acquired 85% equity stake in Arinna Lifesciences for approximately ₹175.92 crore (enterprise value ₹200 crore). The acquisition marks Rubicon's strategic entry into India's domestic CNS formulations market, leveraging Arinna's established distribution network and prescriber base to deploy its US pipeline of commercialized and development-stage products.
• WHO GMP Certified Manufacturing PartnerscoreOthersArinna has 5 manufacturing alliances with WHO GMP certified partners to ensure high quality pharmaceutical products. These partnerships enable the company to maintain quality standards while focusing on marketing and distribution of its CNS portfolio.

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Eris Lifesciences: Eris is an Indian specialty pharma company known for its focus on chronic therapy segments including CNS, cardiology, and diabetology. Its super-specialist field force model and chronic-therapy focus closely parallel Arinna's specialty pharma positioning in India.
• Intas Pharmaceuticals: Intas is the leading CNS specialty pharmaceutical company in India and the previous employer of Arinna's founder. Both companies market branded CNS formulations through field sales forces targeting psychiatrists and neurologists across India, with overlapping therapeutic portfolios in antiepileptics, antidepressants, and antipsychotics.
• Torrent Pharmaceuticals: Torrent Pharma has a meaningful CNS and neuropsychiatry franchise in India, marketing branded formulations in antiepileptics, antipsychotics, and antidepressants through a similar specialty sales motion. Its portfolio depth and prescriber targeting model closely mirror Arinna's ALANZA/ALEXAA divisional structure.
• Alkem Laboratories: Alkem is an Indian specialty pharma company with a strong CNS franchise alongside other therapeutic areas. It competes directly with Arinna in psychiatrist-targeted brands across schizophrenia, depression, and epilepsy segments in the domestic market.

Broad incumbents

• Emcure Pharmaceuticals: Emcure is an Indian pharmaceutical company with a portfolio that includes CNS and women's health brands. Its domestic specialty pharma business and field force targeting of psychiatrists make it a comparable competitor in overlapping CNS therapy areas.
• Mankind Pharma: Mankind is one of India's largest pharma companies by domestic sales with growing CNS presence. While broadly diversified across multiple therapeutic areas, its prescriber field force and aggressive pricing in psychiatry overlaps with Arinna's positioning in CNS.
• Cipla: Cipla is a major Indian pharmaceutical company with a long-standing CNS portfolio and broad distribution across India. It competes with Arinna in core CNS categories including epilepsy, depression, and migraine, while also serving broader therapeutic areas that Arinna does not address.
• Sun Pharmaceutical Industries: Sun Pharma is India's largest pharmaceutical company with a sizable CNS franchise including popular brands in psychiatry and neurology. While diversified across many therapy areas, its CNS portfolio overlaps directly with Arinna's antiepileptic, antidepressant, and antipsychotic offerings, making it a primary share competitor at the prescriber level.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arinna Lifesciences